Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Trametinib in Pediatric Refractory/Relapsed LCH
NCT07890701Phase 2Enrolling by invitation
- Sponsor
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, trametinib in Langerhans cell histiocytosis (LCH), sponsored by The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. Started Oct 2026; status: enrolling by invitation.
02
Drugs
adebrelimabtrametinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT07890701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890701.